BIIB logo

Biogen Inc.

BIIB
Healthcare|Drug Manufacturers - General|US
$248.35
+4.42 (+1.81%)
DCF Value
$517.66
Graham Number
$82.35
Cash / Share
$8.82

Clinical Trials (515)

TrialConditionsPhaseStatusEnrollmentDesignDrug
NCT07223723
A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
P4
Active12Open-labelTofersen
NCT04468659
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
P3
Active1,400RCT, Double-blindLecanemab, Placebo
NCT03887455
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
Early Alzheimer's Disease
P3
Active1,906RCT, Double-blindLecanemab IV, Placebo, Lecanemab SC
NCT06935357
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
Immunoglobulin A Nephropathy (IgAN)
P3
Recruiting454RCT, Double-blindFelzartamab, Placebo
NCT04961567
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
P3
Active562RCT, Double-blindLitifilimab, Placebo
NCT05067790
A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)
Spinal Muscular Atrophy
P3
Active45Open-labelNusinersen
NCT07444476
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam
Spinal Muscular Atrophy
P3
Recruiting90Open-labelSalanersen
NCT07444450
A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec
Muscular Atrophy, Spinal
P3
Recruiting42RCT, Double-blindSalanersen
NCT06953583
A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia
Friedreich Ataxia
P3
Active255RCT, Double-blindOmaveloxolone, Placebo
NCT05531565
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
P2P3
Active450RCT, Double-blindLitifilimab, Placebo
NCT07221669
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
Muscular Atrophy, Spinal
P3
Recruiting30Open-labelSalanersen
NCT06602193
Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)
Parkinson Disease
P2
Active50RCT, Double-blindBIIB122 225 mg
NCT07294144
Tofersen in Non-SOD1 ALS
ALS (Amyotrophic Lateral Sclerosis)
P2
Recruiting30Open-labelTofersen
NCT05418010
Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)
Multiple Sclerosis, Clinically Isolated Syndrome of Demyelination
P2
Recruiting40RCT, Double-blindTyruko Injectable Product, Placebo
NCT07722546
A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old
Graves' Disease
P2
Recruiting60RCT, Double-blindFelzartamab, Placebo
NCT06555419
A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)
Muscular Atrophy, Spinal
P1
Recruiting78Open-labelNusinersen
NCT07133828
A Study to Learn About the Safety of BIIB142 and How it is Processed in the Body of Healthy Adult Participants Aged 18 to 55 Years Old
Healthy Volunteer
P1
Recruiting78RCT, Double-blindBIIB142, BIIB142-Matching Placebo
NCT06054893
A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old
Friedreich Ataxia
P1
Active33Open-labelOmaveloxolone
NCT07662148
A Study to Learn More About the Safety of a Single Dose of BIIB144 and How it is Processed in the Body of Healthy Adult Participants Ages 18 to 55 Years Old as Compared to a Placebo
Healthy Volunteer
P1
Recruiting48RCT, Double-blindBIIB144, Placebo
NCT05575011
A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene Abeparvovec
Healthy Volunteer, Muscular Atrophy, Spinal
P1
Active62RCT, Double-blindBIIB115, BIIB115-Matching Placebo
NCT03047369
The Myelin Disorders Biorepository Project
Leukodystrophy, White Matter Disease
Recruiting12,000——
NCT05866419
Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy
Spinal Muscular Atrophy, Spine Deformity
N/A
Recruiting90Open-label—
NCT01848028
PsoBest - The German Psoriasis Registry
Psoriasis, Psoriatic-arthritis
Recruiting3,500——
NCT05658497
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
Multiple Sclerosis
Recruiting908—Diroximel Fumarate, Avonex, Tysabri, Dimethyl Fumarate
NCT05618379
Adult Spinal Muscular Atrophy (SMA) China Registry
Muscular Atrophy, Spinal
Active200——
NCT05767736
A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)
Multiple Sclerosis
Active10,500—Diroximel Fumarate, Dimethyl Fumarate, Disease-Modifying Therapies (DMTs)
NCT07433010
German Dementia Registry
Dementia Disorder
Recruiting5,000——
NCT07259980
A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
Recruiting125—Tofersen
NCT06623890
A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors
Friedreich Ataxia
Recruiting300—Omaveloxolone
NCT06978985
Adult SMA Research and Clinical Hub
Spinal Muscular Atrophy (SMA)
Recruiting600—Risdiplam, Nusinersen Injectable Product
NCT06955897
Characterizing Perceived Physical Fatigability in Nusinersen-treated SMA
Spinal Muscular Atrophy
Recruiting45——
NCT05042921
Pediatric Spinal Muscular Atrophy (SMA) China Registry
Muscular Atrophy, Spinal
Active600——
NCT05789758
A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA) Who Took it Before or During Pregnancy And About The Health of Their Babies
Muscular Atrophy, Spinal
Recruiting20——
NCT05925049
A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)
Multiple Sclerosis
Active400—Natalizumab
NCT06053749
An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
Multiple Sclerosis (MS)
Active4—Avonex (IFNβ-1-a, Biogen Netherlands B.V), Rebif (IFNβ-1-a, Merck Europe B.V.), Extavia (IFNβ-1-b, Novartis Europharm Limited), Betaseron (IFN-β-1-b, BAY86-5046, Bayer AG), Plegridy (Peg IFNβ-1-a, Biogen Netherlands B.V), MS disease modifying drugs (MSDMDs)
NCT07400198
Gait and Bone Health in SMA
Spinal Muscular Atrophy Type 3, Ambulatory Spinal Muscular Atrophy
Recruiting22——
NCT04317794
A Study of the Safety of Nusinersen (Spinraza®) and Its Effects on Motor Function in Koreans Living With SMA Treated During Their Usual Medical Care
Muscular Atrophy, Spinal
Active74—Nusinersen Sodium Injection
NCT06628687
A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their Babies
Friedreich Ataxia
Recruiting10—Omaveloxolone
NCT07398469
A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting Zuranolone
Postpartum Depression
Recruiting300—Zuranolone
NCT05017142
Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)
Optic Neuritis, Transverse Myelitis
Recruiting500——
NCT04292574
UK SMA Patient Registry
Spinal Muscular Atrophy, SMA
Recruiting800——
NCT00168753
Community Based Trial for AMEVIVE®
Moderate to Severe Chronic Plaque Psoriasis
P4
Completed114Open-labelAlefacept
NCT04048577
A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
P4
Unknown10Open-labelDosing Interruption of Natalizumab
NCT03424733
Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects
Multiple Sclerosis
P4
Unknown50Open-labelPlegridy, Prednisone, Tylenol Pill
NCT00498368
Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy
IgA Nephropathy
P4
Completed34RCT, Open-labelIntravenous Rituximab, ACE/ARB
NCT00574041
How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose
Relapsing Remitting Multiple Sclerosis
P4
Terminated19RCT, Single-blindInterferon beta-1a
NCT00492466
Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies
Relapsing-Remitting Multiple Sclerosis
P4
Completed14Open-labelInterferon-beta-1a, methylprednisolone
NCT02461069
Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
P4
Completed67Open-labelDimethyl fumarate
NCT00913666
Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers
Multiple Sclerosis
P4
Completed121Single-blindInterferon beta-1a (Avonex)
NCT00536120
The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis
Multiple Sclerosis
P4
Completed60RCT, Open-labelBG00002 (natalizumab), keyhole limpet hemocyanin (KLH), tetanus diphtheria toxoid vaccine (Td)
NCT00168766
Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS
Relapsing-remitting Multiple Sclerosis
P4
Completed345RCT, Double-blindInterferon-beta-1a (Avonex) plus methylprednisolone
NCT00493116
Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta
Relapsing-Remitting Multiple Sclerosis
P4
Completed20Open-labelInterferon-beta-1a, methylprednisolone
NCT00801125
Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy
Crohn's Disease
P4
Withdrawn—Open-labelnatalizumab
NCT00744679
A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State
Multiple Sclerosis
P4
Completed20Open-labelNatalizumab
NCT02471560
Tecfidera and the Gut Microbiota
Multiple Sclerosis, Relapsing-Remitting
P4
Completed36Open-labeldimethyl fumarate, injectable MS DMT
NCT00090038
Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
P4
Completed168Open-labelrituximab
NCT00771043
A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a
Relapsing-remitting Multiple Sclerosis
P4
Withdrawn—RCT, Open-labelTYSABRI and AVONEX
NCT01873417
Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States
Relapsing Forms of Multiple Sclerosis
P4
Completed237Open-labelBG00012 (DMF)
NCT02410278
Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera
Multiple Sclerosis
P4
Completed102RCT, Double-blinddimethyl fumarate, montelukast, Placebo
NCT05177718
Natalizumab and Chronic Inflammation
Multiple Sclerosis
P4
Terminated1Open-labelNatalizumab 300 MG in 15 ML Injection
NCT02739542
Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)
Multiple Sclerosis (MS)
P4
Completed87RCT, Double-blindTecfidera, Placebo
NCT00168727
Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma
Lymphoma, Non-Hodgkin, Lymphoma, Low-Grade
P4
Completed12Open-labelibritumomab tiuxetan (Zevalin®)
NCT01767493
Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients
Multiple Sclerosis
P4
Completed19Open-label[18F]Florbetapir PET imaging
NCT05658484
A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China
Multiple Sclerosis
P4
Completed60Open-labelDimethyl fumarate
NCT02143167
Resistance Training and Amino Pyridine in Multiple Sclerosis
Multiple Sclerosis
P4
Completed40RCT, Double-blindSR-fampridine, Placebo
NCT02587065
Plegridy Satisfaction Study in Participants
Relapsing-Remitting Multiple Sclerosis (RRMS)
P4
Completed193Open-labelpeginterferon beta-1a
NCT03177083
Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy
Relapsing Remitting Multiple Sclerosis
P4
Completed80RCT, Open-labelpeginterferon beta-1a, interferon beta-1a, interferon beta-1b
NCT03092544
Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients
Multiple Sclerosis
P4
Unknown57Open-labeldimethyl fumarate
NCT01480076
Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis
Multiple Sclerosis
P4
Completed901Open-labelFampridine
NCT01211665
Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS)
Immune Reconstitution Inflammatory Syndrome, Leukoencephalopathy, Progressive Multifocal
P4
Terminated3Open-labelMethylprednisolone, Prednisolone
NCT00280956
Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease
Crohn's Disease
P4
Completed2,000Open-labelnatalizumab
NCT02142205
Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
Relapsing-Remitting Multiple Sclerosis
P4
Completed100Open-labelBG00002
NCT02090348
Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
P4
Withdrawn—Open-labeldimethyl fumarate
NCT02343159
Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.
Multiple Sclerosis
P4
Terminated84RCT, Open-labeldimethyl fumarate
NCT02568111
Brimonidine Tartrate for the Treatment of Injection Related Erythema
Relapsing-Remitting Multiple Sclerosis (RRMS)
P4
Withdrawn—RCT, Double-blindpeginterferon beta-1a, brimonidine tartrate, Vehicle Gel
NCT00246324
Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis
Multiple Sclerosis
P4
Completed16Open-labelInterferon beta 1a, oral doxycycline
NCT01656148
FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra
Multiple Sclerosis
P4
Completed108RCT, Double-blindFampridine-SR
NCT02683863
Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers
Multiple Sclerosis
P4
Completed20Open-labelBG00012 (DMF) (Tecfidera®.)
NCT02234869
Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy
Relapsing Multiple Sclerosis
P4
Withdrawn—RCT, Open-labelInterferon Beta, BIIB017 (Peginterferon beta-1a)
NCT00492765
Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis
Multiple Sclerosis
P4
Completed380RCT, Double-blindInterferon-beta-1a, Simvastatin, Placebo
NCT02241785
Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies
Relapsing Multiple Sclerosis
P4
Terminated47Open-labelnatalizumab
NCT00179478
Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis
Multiple Sclerosis, Optic Neuritis
P4
Completed155RCT, Single-blindinterferon beta 1a 30 ug IM once weekly
NCT00112034
AVONEX® Combination Trial - "ACT"
Multiple Sclerosis, Relapsing-Remitting
P4
Completed350RCT, Double-blindMethotrexate, IV methylprednisolone
NCT02217982
Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation
Relapsing Remitting Multiple Sclerosis
P4
Terminated5RCT, Open-labelSimethicone, Loperamide
NCT01591551
NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness
Multiple Sclerosis, Relapsing-Remitting
P4
Completed37Open-labelNatalizumab (Tysabri)
NCT04488133
A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (RESPOND)
Muscular Atrophy, Spinal
P4
Completed46Open-labelNusinersen
NCT01556685
MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia
Multiple Sclerosis
P4
Completed180——
NCT02675413
Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
P4
Withdrawn—Open-labelDimethyl Fumarate
NCT00871780
A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients
Relapsing Remitting Multiple Sclerosis (RRMS)
P4
Completed224Open-labelBG00002 (natalizumab)
NCT02342704
Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
Relapsing-Remitting Multiple Sclerosis
P4
Terminated111RCT, Open-labelnatalizumab, fingolimod
NCT01930708
A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
P4
Completed1,114Open-labeldimethyl fumarate
NCT00915460
Open-Label Safety Extension Study of Avonex
Multiple Sclerosis
P4
Completed408Open-labelInterferon beta-1a (Avonex)
NCT02090413
Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
P4
Completed241RCT, Double-blinddimethyl fumarate, acetylsalicylic acid, ASA-Placebo
NCT00037102
Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis
Multiple Sclerosis
P4
Completed16Open-labelinterferon beta 1a, methotrexate
NCT02125604
Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany
Relapsing-Remitting Multiple Sclerosis
P4
Completed214Open-labeldimethyl fumarate
NCT02956486
A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease
Alzheimer's Disease
P3
Terminated2,212RCT, Double-blindElenbecestat, Placebo
NCT00660959
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia
Hyponatremia With Normal Extracellular Fluid Volume
P3
Completed106RCT, Double-blindlixivaptan, placebo
NCT02623699
An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
P3
Completed176RCT, Double-blindTofersen, Placebo
NCT00876876
International, Multicenter, Open-Label and Randomized Withdrawal Study of Oral Lixivaptan in Heart Failure Patients With Chronic Hyponatremia
Hypervolemic Hyponatremia
P3
Withdrawn300RCT, Open-labelLixivaptan
NCT02634307
A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1
Multiple Sclerosis
P3
Completed1,057Open-labelALKS 8700
NCT00578695
THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation
Hyponatremia
P3
Completed652RCT, Double-blindlixivaptan, Placebo
NCT03070119
Long-Term Evaluation of BIIB067 (Tofersen)
ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation
P3
Completed139Open-labelTofersen
NCT00090051
FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients
Chronic Lymphocytic Leukemia
P3
Completed552RCT, Open-labelRituximab, Fludarabine Phosphate, Cyclophosphamide
NCT00774202
Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP
Immune Thrombocytopenic Purpura
P2P3
Completed17RCT, Single-blindRituxan, Cyclophosphamide, Vincristine, Prednisone, Higher Dose of Rituximab
NCT00673556
A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate
Chronic Plaque Psoriasis
P3
Completed195RCT, Double-blindalefacept, placebo
NCT00674063
A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis
Chronic Plaque Psoriasis
P3
Completed78RCT, Double-blindalefacept
NCT00443651
A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis
Rheumatoid Arthritis
P3
Completed578Open-labelRituximab, Anti-inflammatory drugs
NCT03093324
A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2
Relapsing Remitting Multiple Sclerosis
P3
Completed506RCT, Double-blindALKS 8700, Dimethyl Fumarate
NCT05418673
A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale
Parkinson Disease
P3
Terminated7RCT, Double-blindBIIB122, BIIB122-Matching Placebo
NCT00692172
Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During Treatment of Chronic Plaque Psoriasis
Psoriasis
P3
Completed175Open-labelAlefacept
NCT00876798
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia
Euvolemic Hyponatremia
P3
Completed206RCT, Double-blindLixivaptan, Placebo
NCT01440101
Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Sclerosis
P2P3
Completed106RCT, Double-blindNatalizumab (BG00002), Placebo
NCT04729907
A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)
Muscular Atrophy, Spinal
P3
Completed115Double-blindNusinersen
NCT01568112
Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate
Healthy
P3
Completed173RCT, Double-blindBG00012 (dimethyl fumarate), BG00012 placebo, ASA, ASA placebo
NCT02657356
Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST
Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
P3
Terminated202RCT, Double-blindPlacebo capsules, Bardoxolone methyl capsules
NCT07483632
A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)
Relapsing Forms of Multiple Sclerosis
P3
Not Yet Recruiting185RCT, Double-blindDiroximel Fumarate, Dimethyl Fumarate, Fingolimod, Placebo matching DRF, Placebo matching DMF, Placebo matching fingolimod
NCT05310071
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
Alzheimer's Disease
P3
Terminated1,027RCT, Double-blindAducanumab, Placebo
NCT07444489
A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)
Antibody-mediated Rejection, Microvascular Inflammation
P3
By Invite201Open-labelFelzartamab
NCT01351675
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
P3
Terminated2,185RCT, Double-blindPlacebo, Bardoxolone Methyl: 20 mg
NCT00168740
Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)
Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma
P3
Completed150Open-labelrituximab
NCT05083923
A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)
Relapsing Forms of Multiple Sclerosis
P3
Completed136Open-labelDiroximel fumarate
NCT00384150
Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)
Lymphoma, Non-Hodgkin's
P3
Terminated16Open-labelgaliximab in combination with rituximab
NCT01337427
Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis
Relapsing Remitting Multiple Sclerosis
P3
Withdrawn—RCT, Double-blindBIIB017
NCT03672175
A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder
Major Depressive Disorder
P3
Completed581RCT, Double-blindSAGE-217, Placebo
NCT01622088
Phase 3 Extension Study of Dexpramipexole in ALS
Amyotrophic Lateral Sclerosis
P3
Terminated616Open-labelDexpramipexole
NCT01917019
A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis
Multiple Sclerosis, Remittent Progressive, Multiple Sclerosis, Primary Progressive
P3
Completed101RCT, Double-blindPlacebo, BIIB041 (fampridine)
NCT00835770
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
Relapsing-Remitting Multiple Sclerosis
P3
Completed1,736RCT, Double-blinddimethyl fumarate, Placebo
NCT00828204
Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects
Multiple Sclerosis
P3
Completed95Open-labelBG9418 (interferon beta-1a)
NCT01332019
Long-Term Safety and Efficacy Study of Peginterferon Beta-1a
Relapsing Multiple Sclerosis
P3
Completed1,077Open-labelpeginterferon beta-1a
NCT00276172
Open-Label Natalizumab Safety Extension Study
Multiple Sclerosis
P3
Completed1,615Open-labelNatalizumab
NCT04442503
A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)
Depression, Postpartum
P3
Completed200RCT, Double-blindSAGE-217, Placebo
NCT00297232
Natalizumab (Tysabri) Re-Initiation of Dosing
Relapsing-Remitting Multiple Sclerosis
P3
Terminated1,094Open-labelNatalizumab
NCT05352919
A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus (SLE)
P3
By Invite864RCT, Double-blindLitifilimab, Litifilimab-matching placebo
NCT01235221
Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.
Multiple Sclerosis
P3
Completed38Open-labelBIIB041 (Fampridine-SR)
NCT04007367
A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder
Major Depressive Disorder
P3
Terminated53RCT, Double-blindSAGE-217, Placebo
NCT00233662
Safety and Tolerability of Repeat Courses of IM Alefacept
Chronic Plaque Psoriasis
P3
Completed400Open-labelAlefacept
NCT02428218
Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Relapsing-Remitting Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis
P3
Withdrawn—RCT, Double-blinddimethyl fumarate, Placebo
NCT02881567
Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab
Relapsing-Remitting Multiple Sclerosis (RRMS)
P3
Terminated41Open-labelDaclizumab
NCT00223301
Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis
Multiple Sclerosis
P2P3
Completed24RCT, Double-blindMycophenolate Mofetil (cellcept)
NCT02428231
Tecfidera Slow-Titration Study
Multiple Sclerosis
P3
Terminated62RCT, Double-blinddimethyl fumarate
NCT00906399
Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis
Relapsing Multiple Sclerosis
P3
Completed1,516RCT, Double-blindBIIB017 (peginterferon beta-1a), Placebo
NCT01939002
Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)
Relapsing Multiple Sclerosis
P3
Completed251RCT, Open-labelBIIB017, naproxen
NCT00420212
Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
P3
Completed1,234RCT, Double-blindBG00012, Placebo
NCT02555215
Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
Multiple Sclerosis, Relapsing-Remitting
P3
Completed20Open-labeldimethyl fumarate
NCT02430532
BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis
Multiple Sclerosis, Secondary Progressive
P3
Terminated58RCT, Double-blinddimethyl fumarate
NCT03068130
Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER
Pulmonary Hypertension
P3
Terminated261Open-labelBardoxolone methyl
NCT01416181
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
Secondary Progressive Multiple Sclerosis
P3
Terminated889RCT, Double-blindnatalizumab, Placebo
NCT00306592
Natalizumab Re-Initiation of Dosing
Multiple Sclerosis, Relapsing-Remitting
P3
Completed404Open-labelBG00002 (natalizumab)
NCT00027300
Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
P3
Completed900RCT, Double-blindNatalizumab, Placebo
NCT02292537
A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA)
Spinal Muscular Atrophy
P3
Completed126RCT, Double-blindNusinersen
NCT00784836
Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients
Multiple Sclerosis
P3
Terminated3Open-labelBG9418 (interferon beta 1-a)
NCT04476030
A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder
Depressive Disorder, Major
P3
Completed440RCT, Double-blindSAGE-217, Matching Placebo, Sertraline, Escitalopram, Citalopram, Duloxetine, Desvenlafaxine
NCT04241068
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
Alzheimer's Disease
P3
Terminated1,696Open-labelAducanumab
NCT00078611
A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease
Crohn's Disease
P3
Completed462RCT, Double-blindnatalizumab
NCT00697996
Rituximab for Pediatric Renal Transplant Rejection
Kidney Transplantation
P2P3
Completed20RCT, Open-labelRituximab for transplant rejection
NCT04442490
A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)
Depressive Disorder, Major
P3
Completed543RCT, Double-blindSAGE-217, Placebo
NCT00057343
Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
P3
Terminated400RCT, Open-labelZevalin (ibritumomab tiuxetan), Rituxan (rituximab)
NCT02477800
221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
Alzheimer's Disease
P3
Terminated1,653RCT, Double-blindAducanumab (BIIB037), Aducanumab (BIIB037), Placebo
NCT05265728
A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
P3
Terminated21Open-labelNatalizumab
NCT00030966
Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
P3
Completed1,200RCT, Double-blindNatalizumab, Placebo
NCT03771664
A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia
Major Depressive Disorder, Insomnia
P3
Terminated87RCT, Double-blindSAGE-217, Placebo
NCT03070132
802NP301 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia
Trigeminal Neuralgia
P3
Withdrawn—RCT, Double-blindBIIB074, Placebo
NCT01797965
Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
P3
Terminated1,501Open-labelBIIB019 (Daclizumab)
NCT03870763
Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants
Multiple Sclerosis, Relapsing-Remitting
P3
Terminated11RCT, Double-blindDimethyl Fumarate, Peginterferon Beta-1a, Placebo
NCT02978326
A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression
Postpartum Depression
P3
Completed276RCT, Double-blindSAGE-217 15/20 mg Oral Solution, Placebo, SAGE 217 30 mg Capsules
NCT00032786
Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease
Crohn's Disease
P3
Completed—RCT, Double-blindnatalizumab
NCT03584165
Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa
Choroideremia, X-Linked Retinitis Pigmentosa
P3
Completed277Single-blind—
NCT00032799
Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease
Crohn's Disease
P3
Completed905RCT, Double-blindnatalizumab
NCT02283853
Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Relapsing-Remitting Multiple Sclerosis
P3
Completed156RCT, Open-labeldimethyl fumarate, Interferon β-1a
NCT00915577
Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe
Multiple Sclerosis
P3
Completed74Open-labelInterferon beta-1a
NCT03496012
Efficacy and Safety of BIIB111 for the Treatment of Choroideremia
Choroideremia
P3
Completed169RCT, Single-blind—
NCT01838668
An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
P3
Completed225RCT, Double-blindPlacebo, dimethyl fumarate
NCT02594124
A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies
Spinal Muscular Atrophy
P3
Completed292Open-labelnusinersen
NCT00451451
Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
P3
Completed1,417RCT, Double-blindBG00012, Placebo, Glatiramer Acetate
NCT06044337
A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
P3
By Invite306Open-labelBIIB059 (litifilimab)
NCT02097745
A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies
Rheumatoid Arthritis
P3
Completed341Open-labelmethotrexate, rituximab [MabThera/Rituxan]
NCT03918447
A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON
Autosomal Dominant Polycystic Kidney, ADPKD
P3
Terminated667RCT, Double-blindBardoxolone methyl oral capsule, Placebo oral capsule
NCT00106184
Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)
Myositis, Dermatomyositis
P2
Completed200RCT, Double-blindRituximab, Placebo
NCT00290511
Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma
Lymphoma
P2
Completed49Open-labelFludarabine, Mitoxantrone, Rituximab, Zevalin, Dexamethasone
NCT02322021
Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease
Alzheimer Disease, Dementia, Alzheimer Type
P2
Terminated70RCT, Double-blindE2609, Placebo
NCT00584935
Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid
Ocular Cicatricial Pemphigoid
P1P2
Completed3Open-labelRituximab
NCT00588822
Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance
Precancerous Condition
P2
Terminated21Open-labelRituximab
NCT00642655
Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation
Kidney Transplant
P1P2
Completed20Open-labelIVIG and Rituximab
NCT00379587
Rituximab for Prevention of Chronic GVHD
Hematological Malignancies
P1P2
Completed65Open-labelRituximab, 375 mg/m2 RRituximab
NCT05348785
A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80
Parkinson Disease
P2
Completed650RCT, Double-blindBIIB122, BIIB122-Matching Placebo
NCT00424749
Rituxan in Churg Strauss Syndrome With Renal Involvement
Churg-Strauss Syndrome
P2
Terminated4Open-labelRituximab, Prednisone
NCT01767311
A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease
Alzheimer's Disease
P2
Completed856RCT, Double-blindLecanemab 2.5 mg/kg, Lecanemab 5.0 mg/kg, Lecanemab 10 mg/kg, Lecanemab 5.0 mg/kg, Lecanemab 10 mg/kg, Placebo, Lecanemab 10 mg/kg
NCT00659412
A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis
Psoriatic Arthritis
P2
Completed185RCT, Double-blindAlefacept, Methotrexate, Placebo
NCT01713738
Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
Idiopathic Thrombocytopenic Purpura (ITP), Immune Thrombocytopenic Purpura (ITP)
P1P2
Completed36Open-labelrituximab
NCT00298272
Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis
Rheumatoid Arthritis
P2
Terminated54RCT, Double-blindIDEC-C2B8 (rituximab), Placebo, Methotrexate, Etanercept, Adalimumab, Methylprednisolone
NCT00280241
Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
P2
Completed65Open-labelFludarabine, Cyclophosphamide, Rituximab
NCT00117156
Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma
Lymphoma, Non-Hodgkin, MALT Lymphoma
P2
Completed26Open-labelFludarabine, Rituximab
NCT01004081
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Breast Cancer
P2
Completed54RCT, Open-labelBIIB021, BIIB021, exemestane (Aromasin)
NCT00301002
Study to Evaluate the Efficacy of Alefacept to Treat Palmar Plantar Pustulosis
Psoriasis, Palmoplantaris Pustulosis
P2
Completed15Open-labelAlefacept
NCT00048737
Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies
Lymphoma, Leukemia
P1P2
Completed70Open-labelZevalin Radioimmunotherapy, Rituximab, Fludarabine, Cyclophosphamide
NCT01077466
Natalizumab Treatment of Progressive Multiple Sclerosis
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
P2
Completed24Open-labelNatalizumab
NCT03507686
A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111
Choroideremia
P2
Completed66Open-labelBIIB111
NCT00369395
A Study of Volociximab in Metastatic Melanoma
Stage IV Melanoma
P2
Terminated19Open-labelvolociximab
NCT05065970
Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy
Immunoglobulin A (IgA) Nephropathy
P2
Completed54RCT, Double-blindFelzartamab
NCT02255435
A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia
Friedreich Ataxia
P2
Completed172RCT, Double-blindOmaveloxolone Capsules, 2.5 mg, Omaveloxolone Capsules, 5 mg, Omaveloxolone Capsules, 10 mg, Placebo, Omaveloxolone Capsules, 20 mg, Omaveloxolone Capsules, 40 mg, Omaveloxolone Capsules, 80 mg, Omaveloxolone Capsules, 160 mg, Omaveloxolone Capsules, 300 mg, Omaveloxolone Capsules, 150 mg
NCT04145440
Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)
Glomerulonephritis, Membranous, antiPLA2R Positive
P1P2
Completed31Open-labelMOR202
NCT02730455
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Acute Ischemic Stroke
P2
Completed277RCT, Double-blindnatalizumab, Placebo
NCT04702997
A Trial of Bardoxolone Methyl in Patients With CKD at Risk of Rapid Progression (MERLIN)
Chronic Kidney Diseases
P2
Completed81RCT, Double-blindBardoxolone methyl oral capsule, Placebo oral capsule
NCT03000569
A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease
Parkinson Disease
P2
Completed29Open-labelSAGE-217, Levodopa, Antiparkinsonian Agent(s)
NCT03692910
A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode
Bipolar Disorder I, Bipolar Disorder II
P2
Completed35Open-labelSAGE-217, Placebo
NCT00635193
Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)
Ovarian Cancer, Primary Peritoneal Cancer
P1P2
Completed138RCT, Open-labelM200 (Volociximab), Liposomal Doxorubicin, M200 (Volociximab), M200 (Volociximab)
NCT02065375
RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery
Inflammation and Pain Following Ocular Surgery
P2
Completed109RCT, Double-blindOmaveloxolone Ophthalmic Suspension 1.0%, Omaveloxolone Opthalmic Suspension 0.5%, Placebo
NCT03318523
Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease
Parkinson's Disease
P2
Terminated357RCT, Double-blindPlacebo, BIIB054
NCT00000659
A Phase II Trial of rsCD4 and AZT in Patients With AIDS or Advanced AIDS Related Complex (ARC)
HIV Infections
P2
Terminated80Open-labelCD4 Antigens, Zidovudine
NCT00493467
Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas
Lymphoma
P2
Completed31Open-labelIbritumomab Tiuxetan (Zevalin), Rituximab
NCT03366337
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
IgA Nephropathy, CKD Associated With Type 1 Diabetes
P2
Completed103Open-labelBardoxolone methyl capsules
NCT00516841
A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer
Ovarian Cancer, Peritoneal Neoplasms
P2
Terminated16Open-labelVolociximab
NCT00912860
Immunogenicity and Safety Study of Serum-Free Avonex
Multiple Sclerosis
P2
Completed155Open-labelInterferon beta-1a
NCT00493454
Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas
Lymphoma
P2
Terminated6Open-labelZevalin, Rituximab, ^111 In Ibritumomab Tiuxetan
NCT00442780
Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's Disease
Parkinson's Disease
P2
Completed36RCT, Double-blindBIIB014, Placebo
NCT05798520
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)
Relapsing Forms of Multiple Sclerosis
P2
Completed127RCT, Double-blindBIIB091, DRF, Placebo
NCT00831649
A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201
Rheumatoid Arthritis
P2
Terminated—Open-labelnatalizumab
NCT02959658
Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis
Primary Progressive Multiple Sclerosis
P2
Completed54RCT, Double-blindDimethyl fumarate, Placebo
NCT01864148
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
Multiple Sclerosis
P2
Completed419RCT, Double-blindBIIB033, Avonex
NCT04733040
Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE)
Glomerulonephritis, Membranous Nephropathy
P2
Completed24RCT, Open-labelMOR202
NCT00390221
Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
P2
Completed621RCT, Double-blindBIIB019 (Daclizumab High Yield Process), Placebo
NCT00811889
Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease
Chronic Kidney Disease, Type 2 Diabetes
P2
Completed227RCT, Double-blindBardoxolone Methyl (RTA 402)
NCT00664573
104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants
Rheumatoid Arthritis
P2
Terminated339RCT, Double-blindBaminercept alfa (BG9924)
NCT01721161
BIIB033 In Acute Optic Neuritis (AON)
Acute Optic Neuritis
P2
Completed82RCT, Double-blindBIIB033 (anti-LINGO-1 mAb), Placebo
NCT00438607
Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate to Late Stage Parkinson's Disease
Parkinson's Disease
P2
Completed83RCT, Double-blindBIIB014, Placebo
NCT02386553
A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
Spinal Muscular Atrophy
P2
Completed25Open-labelNusinersen
NCT02410200
Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS
Multiple Sclerosis, Relapsing-Remitting
P2
Completed22Open-labeldimethyl fumarate
NCT01597297
Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis.
Multiple Sclerosis
P2
Completed132RCT, Double-blindBIIB041 (PR Fampridine)
NCT00083759
Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate
Rheumatoid Arthritis
P2
Terminated299RCT, Double-blindnatalizumab, placebo
NCT03339336
Efficacy and Safety Study of BIIB074 in Participants With Small Fiber Neuropathy
Small Fiber Neuropathy, Diabetes Mellitus
P2
Terminated265RCT, Double-blindBIIB074, Placebo
NCT02128113
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
Corneal Endothelial Cell Loss, Ocular Pain
P2
Completed307RCT, Double-blindVehicle Ophthalmic Solution, Omaveloxolone Ophthalmic Suspension 0.5%, Omaveloxolone Ophthalmic Suspension 1%
NCT00516893
Natalizumab High Titer Immunogenicity and Safety
Multiple Sclerosis
P2
Completed113Open-labelBG00002-E (natalizumab high titer)
NCT03068468
Study of BIIB092 in Participants With Progressive Supranuclear Palsy
Supranuclear Palsy, Progressive
P2
Terminated490RCT, Double-blindBIIB092, Placebo
NCT01703988
An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy
Spinal Muscular Atrophy
P1P2
Completed34Open-labelNusinersen
NCT02255422
RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR
MItochondrial Myopathies
P2
Completed53RCT, Double-blindOmaveloxolone capsules, 2.5 mg, omaveloxolone capsules, 5 mg, omaveloxolone capsules, 10 mg, Placebo capsules, omaveloxolone capsules, 20 mg, omaveloxolone capsules, 40 mg, omaveloxolone capsules, 80 mg, omaveloxolone capsules, 160 mg
NCT00055367
Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease
Crohn's Disease
P2
Completed30Open-labelnatalizumab
NCT02847598
Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus, Active Cutaneous Lupus Erythematosus
P2
Completed264RCT, Double-blindBIIB059 (litifilimab), Placebo
NCT02462759
A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA).
Spinal Muscular Atrophy
P2
Terminated21RCT, Double-blindNusinersen
NCT00031642
Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation
Lymphoma
P1P2
Completed26Open-labelrituximab
NCT00458861
BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid Arthritis
Rheumatoid Arthritis
P2
Terminated115RCT, Double-blindBG9924
NCT03745820
A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)
Cognitive Impairment Associated With Schizophrenia
P2
Completed195RCT, Double-blindBIIB104
NCT00135733
A Safety and Efficacy Study of Alefacept in the Treatment of Moderate to Severe Erosive Mucosal Lichen Planus
Lichen Planus
P2
Terminated13RCT, Double-blindAmevive (Alefacept), Placebo
NCT00292422
Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheumatoid Arthritis
Rheumatoid Arthritis
P2
Completed50RCT, Double-blindBG9924
NCT00664716
Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Participants
Rheumatoid Arthritis
P2
Completed391RCT, Double-blindBaminercept alfa 1, Placebo, Baminercept alfa 2, Baminercept alfa 3, Baminercept alfa 4, Baminercept alfa 5
NCT00523328
BG9924 in Combination With Methotrexate Extension of Study 104RA203 (NCT 00458861)
Rheumatoid Arthritis
P2
Terminated72Open-labelBG9924
NCT05173012
Study to Evaluate SAGE-324 in Participants With Essential Tremor
Essential Tremor
P2
Completed146RCT, Double-blindSAGE-324, SAGE-324 Matched Placebo
NCT02036970
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
Pulmonary Arterial Hypertension, Pulmonary Hypertension
P2
Completed166RCT, Double-blindBardoxolone methyl, Placebo
NCT01181089
Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)
Secondary Progressive Multiple Sclerosis
P1P2
Withdrawn—RCT, Double-blindPlacebo, Baminercept
NCT00801060
Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
P2
Terminated40RCT, Open-labelLumiliximab + FCR, FCR
NCT00726648
CDP323 Biomarker Study
Relapsing Multiple Sclerosis
P1P2
Completed71RCT, Double-blindCDP323, CDP323, CDP323, CDP323, Placebo
NCT01499355
BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis
Lupus Nephritis
P2
Terminated276RCT, Double-blindBIIB023, Placebo, mycophenolate mofetil, oral corticosteroids
NCT00119730
Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma
Mantle Cell Lymphoma
P2
Completed30Open-labelFludarabine, Mitoxantrone, Rituximab, Zevalin
NCT00005592
Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Lymphoma
P2
Completed23Open-label90-Y-ibritumomab tiuxetan, rituximab
NCT00055536
Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease
Crohn's Disease
P2
Completed60RCT, Double-blindnatalizumab
NCT00391066
Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
P2
Terminated627RCT, Open-labelFCR + Lumiliximab, FCR
NCT02657915
Long-Term Assessment of Remyelinating Therapy
Acute Optic Neuritis
P2
Completed52RCT, Double-blindPlacebo, BIIB033 100mg/Kg
NCT00193440
Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma
Non-Hodgkins Lymphoma
P2
Completed40Open-labelRituximab, CHOP, CVP, Ibritumomab Tiuxetan
NCT02259231
RTA 408 Capsules in Patients With Melanoma - REVEAL
Melanoma, Unresectable (Stage III) Melanoma
P1P2
Completed41Open-labelOmaveloxolone Capsules (2.5 mg/capsule), Ipilimumab (3 mg/kg), Nivolumab (240 mg), Omaveloxolone Capsules (10 mg/capsule), Omaveloxolone Capsules (50 mg/capsule)
NCT01652937
BIIB057 in Subjects With Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs
Rheumatoid Arthritis
P2
Withdrawn—RCT, Double-blindBIIB057, Placebo
NCT01576887
A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effects of Residual Renal Function (RFF) in Patients With End-Stage Renal Disease and Type 2 Diabetes Mellitus on Peritoneal Dialysis
End-Stage Renal Disease, Type 2 Diabetes Mellitus
P2
Withdrawn—RCT, Double-blindBardoxolone Methyl 20 mg, Placebo
NCT01051349
Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
P2
Completed410Open-labelBIIB019 (Daclizumab), trivalent seasonal influenza vaccine
NCT00097760
Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
P2
Completed110RCT, Double-blindNatalizumab, Natalizumab, Placebo
NCT01873404
BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy
Painful Lumbar Radiculopathy, Sciatica
P2
Completed183RCT, Double-blindBG00010, Placebo
NCT01416155
Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
P2
Completed97Open-labelnatalizumab
NCT00810836
Efficacy and Safety Study of BG00012 With Methotrexate in Patients With Active Rheumatoid Arthritis
Rheumatoid Arthritis
P2
Completed153RCT, Double-blindBG00012, BG00012, placebo
NCT00177554
Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma
Non-Hodgkin Lymphoma
P2
Completed60Open-labelChemotherapy and Radioimmunotherapy
NCT03116113
A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112
X-Linked Retinitis Pigmentosa
P1P2
Completed50RCT, Double-blindBIIB112
NCT07889362
A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN)
Immunoglobulin A Nephropathy
P2
Not Yet Recruiting25Open-labelFelzartamab
NCT00107861
Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases
Colorectal Carcinoma, Metastases
P1P2
Completed44Open-labelAd.hIFN-β (BG00001, IDEC-201)
NCT02133924
Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
Acute Graft Versus Host Disease
P2
Completed76Open-labelnatalizumab, steroids
NCT01552681
Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome
Primary Sjögren's Syndrome
P2
Terminated52RCT, Double-blindBaminercept
NCT00616434
A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis
Active Ulcerative Colitis
P2
Completed123RCT, Double-blindBG9418 (Interferon beta-1a), Placebo
NCT03283371
Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy
Epilepsy, Focal Seizures, Partial Seizures
P2
Completed67RCT, Double-blindNatalizumab
NCT05021484
Felzartamab in Late Antibody-Mediated Rejection
Antibody-mediated Rejection
P2
Completed22RCT, Double-blindFelzartamab, Placebo
NCT00099489
Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
P2
Completed67RCT, Double-blindInterferon Beta-1a
NCT01561027
Crossover Study of CNV1014802 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy
Lumbosacral Radiculopathy
P2
Completed82RCT, Double-blindCNV1014802, Placebo
NCT00150982
Alefacept Mechanism of Action in Psoriasis
Psoriasis
P2
Completed9Open-labelMechanism of action of alefacept
NCT00168701
Efficacy and Safety of BG00012 in MS
Multiple Sclerosis
P2
Completed260RCT, Double-blindBG00012
NCT00870740
Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
P2
Completed517RCT, Double-blindBIIB019 (Daclizumab High Yield Process), Placebo
NCT00550849
Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Patients With Hepatic Dysfunction
Liver Disease
P1P2
Terminated16RCT, Double-blindRTA 402, RTA 402, RTA 402
NCT01930890
BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis
Lupus Nephritis
P2
Terminated87RCT, Double-blindBIIB023, mycophenolate mofetil, oral corticosteroids
NCT01538472
Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma
Lymphoma
P1P2
Completed40Open-labelY Zevalin, In Zevalin, Rituxan, BCNU, VP -16, Ara-C, Melphalan, G-CSF
NCT01371305
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis (IPF)
P2
Completed41RCT, Double-blindBG00011, Placebo
NCT00048555
Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
P1P2
Completed90Open-labelIDEC-114
NCT00535314
Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma
Malignant Melanoma
P2
Withdrawn—RCT, Open-labelRTA 402 Dose1, RTA 402 Dose2
NCT00143806
Transitioning From Cyclosporine to Alefacept in Psoriasis
Psoriasis
P2
Completed13Open-labelTransitioning patients from cyclosporine to alefacept
NCT00476515
Rituximab Therapy for Patients on Kidney Transplant Waiting List With Positive Donor Specific Crossmatch to Living Donor
Kidney Insufficiency
P1
Withdrawn—Open-labelRituximab
NCT00675701
A Study to Define the ECG Effects of Lixivaptan Compared to Placebo and Moxifloxacin in Healthy Adult Men and Women: A Thorough ECG Study
Healthy
P1
Completed298RCT, Double-blindplacebo, lixivaptan, moxifloxacin
NCT05005338
A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy Subjects
Healthy Volunteers
P1
Completed8Open-labelBIIB122 (DNL151), [14C] BIIB122 ([14C] DNL151)
NCT05119790
A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite Identification of BIIB122/DNL151 in Healthy Male Subjects
Healthy Volunteers
P1
Completed7Open-label[14C] BIIB122 ([14C] DNL151)
NCT05909644
An Open-label DDI Study of Omaveloxolone in Healthy Subjects
Healthy Adult Subjects
P1
Completed20Open-labelOmaveloxolone, Efavirenz
NCT06741657
A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Under the Skin in 3 Different Ways
Healthy Volunteer
P1
Completed404RCT, Open-labelLitifilimab
NCT02751905
Absorption, Metabolism, and Excretion Study of BIIB074
Neuropathic Pain
P1
Completed6Open-labelBIIB074
NCT01494701
An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA)
Spinal Muscular Atrophy
P1
Completed28Open-labelnusinersen
NCT02341482
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy Subjects
Healthy
P1
Completed13Open-labelPF-04958242, Itraconazole
NCT03626012
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
P1
Completed106RCT, Double-blindBIIB078, Placebo
NCT06454721
A Study to Determine the Biodistribution, Safety, and Tolerability of a Microdose of Radiolabeled Diranersen (BIIB080) Co-administered With Diranersen in Healthy Adults
Healthy Volunteer
P1
Completed5Open-label[89Zr]Zr-DFO-Diranersen, Diranersen
NCT02459886
Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease
Parkinson's Disease, Healthy
P1
Completed66RCT, Double-blindBIIB054, Placebo
NCT02981082
Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
Systemic Sclerosis, Pulmonary; Hypertension
P1
Terminated6RCT, Double-blindDimethyl Fumarate (DMF), Placebo Oral Tablet
NCT00529438
RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies
Advanced Solid Tumors, Lymphoid Malignancies
P1
Completed47Open-labelBardoxolone methyl
NCT00345189
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors
Tumors, Lymphoma
P1
Completed70Open-labelCNF2024
NCT00559702
Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)
Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
P1
Completed76RCT, Open-labelnatalizumab
NCT03324685
A Drug Interaction Study of BIIB074 and an Oral Contraceptive Regimen
Drug Interactions
P1
Completed36Open-labelBIIB074, OC (ethinyl estradiol and levonorgestrel)
NCT01500798
A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With Chronic Kidney Disease and Type 2 Diabetes
Chronic Kidney Disease, Type 2 Diabetes
P1
Terminated18RCT, Double-blind20 mg bardoxolone methyl, Placebo
NCT02551497
Study to Evaluate the Interaction Between a Drug and CNV1014802 in Healthy Subjects
Healthy
P1
Completed36RCT, Double-blindCNV1014802
NCT01052506
BIIB033 Single Ascending Dose Study in Healthy Volunteer Subjects
Healthy
P1
Completed72RCT, Double-blindBIIB033, Placebo
NCT01238679
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PF-04958242 in Healthy Adult Volunteers
Healthy Volunteers
P1
Terminated20RCT, Double-blindPF-04958242, Placebo
NCT01551446
Pilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients With Chronic Kidney Disease and Type 2 Diabetes
Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
P1
Withdrawn—Open-labelBardoxolone Methyl
NCT03385525
Study to Evaluate the Effect of UGT Inhibition by Valproic Acid on the Pharmacokinetics of BIIB074
Drug Interaction
P1
Completed30Open-labelBIIB074, Valproic Acid
NCT00105170
Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors
Tumors
P1
Terminated13Open-labelhCBE-11
NCT00344786
Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL
B-Cell Chronic Lymphocytic Leukemia
P1
Terminated15Open-labelCNF2024 (BIIB021)
NCT01511510
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy Volunteers
Schizophrenia
P1
Completed39RCT, Double-blindPF-04958242, PF-04958242, PF-04958242, PF-04958242, Placebo
NCT00031083
Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas
Glioblastoma Multiforme, Anaplastic Astrocytoma
P1
Completed12Open-label—
NCT02228707
Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers
Healthy
P1
Completed56RCT, Double-blindBIIB061
NCT02269930
Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers
Multiple Sclerosis
P1
Completed30Open-labelpeginterferon beta-1a, Rebif
NCT02951221
New Formulation and Food Effect Study of BIIB074
Trigeminal Neuralgia (TN), Other Neuropathic Pain
P1
Completed28RCT, Open-labelBIIB074 Treatment A, BIIB074 Treatment B, BIIB074 Treatment C, BIIB074 Treatment D
NCT01884935
PK and PD Study of Natalizumab in Pediatric Subjects With RRMS
Relapsing-Remitting Multiple Sclerosis
P1
Completed13Open-labelNatalizumab
NCT02460094
Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy
Progressive Supranuclear Palsy
P1
Completed48RCT, Double-blindBIIB092, Placebo
NCT04924140
A Study to Assess Absolute Bioavailability of Aducanumab in Healthy Volunteers
Healthy Volunteers
P1
Completed30RCT, Open-labelAducanumab
NCT02434718
Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's Disease
Alzheimer's Disease
P1
Completed21RCT, Double-blindAducanumab, Placebo
NCT01518920
A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss
Hearing Loss, Sensorineural
P1
Completed44RCT, Double-blindPF-04958242, PF-04958242, Placebo
NCT00956436
Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma
P1
Completed40Open-labelBIIB022, Sorafenib
NCT01929746
Daclizumab Japanese PK Study
Healthy
P1
Completed56RCT, Single-blindBIIB019 subcutaneous injection
NCT03945279
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
P1
Completed49RCT, Double-blindBIIB100, Placebo
NCT00674947
A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors
Solid Tumors
P1
Completed55Open-labelBIIB015
NCT01244139
Safety Study of BIIB033 in Subjects With Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
P1
Completed47RCT, Double-blindBIIB033, Placebo
NCT01407406
Phase 1 Study to Evaluate the PK, Safety, Tolerability of BIIB023 in Chinese, Japanese, and Caucasian Healthy Volunteers
Healthy Volunteers
P1
Completed48RCT, Double-blindBIIB023 - low dose IV Dose, BIIB023 - high dose IV Dose
NCT02201849
A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults
Multiple Sclerosis
P1
Completed104RCT, Double-blindStudy Drug, Active Control, Placebo
NCT01632449
Study in Healthy Volunteers to Establish the Bioequivalence of Two Different Manufacturers.
Healthy Volunteers
P1
Completed80RCT, Single-blindTest product, Reference product
NCT06311786
A Study to Look at How a Single Oral Dose of Carbon-14-Labelled [14C] BIIB091 Moves Through and is Processed by the Body in Healthy Male Participants
Healthy Volunteer
P1
Completed8Open-label[14C]-BIIB091
NCT01281111
Alternate Dosing Regimens of BG00012 in Healthy Volunteers
Healthy
P1
Completed56RCT, Double-blindDimethyl Fumarate (BG00012), Aspirin, BG00012 matching placebo, ASA matching placebo
NCT00526812
A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas
Glioma
P1
Completed54Open-labelRTA 744, RTA 744 injection
NCT06574828
A Study to Find Out How Multiple Doses of BIIB091 Affect the Electrical Activity of the Heart in Healthy Participants
Healthy Volunteer
P1
Completed69RCT, Double-blindBIIB091, Moxifloxacin, BIIB091-matched Placebo, Moxifloxacin-matched Placebo
NCT06612879
A Study to Find Out How BIIB141 (Omaveloxolone) Moves From the Blood Into the Breastmilk of Healthy Women Who Are Breastfeeding or Pumping Milk
Healthy Volunteer
P1
Completed12Open-labelOmaveloxolone
NCT02833142
Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes
Multiple Sclerosis, Acute Optic Neuritis
P1
Completed28RCT, Double-blindBIIB033 (opicinumab)
NCT02294851
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects
Tauopathies
P1
Completed65RCT, Double-blindBMS-986168, BMS-986168 Placebo
NCT01924832
BG00012 Regional Absorption Study
Healthy
P1
Completed32Open-labeldimethyl fumarate
NCT01749098
A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers
Schizophrenia
P1
Completed29RCT, Double-blindPF-04958242, Ketamine, Placebo, Ketamine
NCT01764594
Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus
Immune System Diseases, Autoimmune Diseases
P1
Completed24RCT, Single-blindCDP7657
NCT07149415
A Study to Learn if Taking BIIB141 (Omaveloxolone) Affects How Omeprazole is Processed in the Body and About BIIB141's Safety in Healthy Adults Aged 18 to 55
Healthy Volunteer
P1
Completed22Open-labelOmaveloxolone, Omeprazole
NCT01461161
A Single-Dose, Open-Label, Randomized, Food Effect and Blinded, Randomized, Dose Proportionality Study in Healthy Volunteers With Bardoxolone Methyl
Healthy Volunteers
P1
Completed32RCT, Double-blindbardoxolone methyl
NCT05618301
Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)
Sickle Cell Disease
P1
Completed10Open-labelMotixafortide, Natalizumab
NCT04008186
A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone
Healthy Adult Subjects
P1
Completed61Open-labelOmaveloxolone, Midazolam oral solution, Repaglinide 1 MG, MetFORMIN 500 Mg Oral Tablet, Rosuvastatin, Digoxin tablet, Gemfibrozil Tablets, Itraconazole capsule, Verapamil Pill
NCT00527410
A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis
Leptomeningeal Carcinomatosis
P1
Terminated9Open-labelRTA 744
NCT03902002
A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function
Hepatic Impairment
P1
Completed48Open-labelOmaveloxolone 50 mg capsules
NCT04056689
Study to Evaluate DNL151 in Subjects With Parkinson's Disease
Parkinson's Disease
P1
Completed36RCT, Double-blindDNL151, Placebo
NCT00771329
BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis
Rheumatoid Arthritis
P1
Completed53RCT, Double-blindBIIB023
NCT02029716
RTA 408 Lotion in Healthy Volunteers
Healthy
P1
Completed109RCT, Double-blindRTA 408 Lotion 0.5%, 1%, 3%, Lotion vehicle/placebo
NCT02443740
Safety, Tolerability and Pharmacokinetics of BIIB118 (PF-05251749)
Healthy
P1
Completed32RCT, Double-blindBIIB118, BIIB118, BIIB118
NCT01863069
Avonex®: Safety, Blood Levels and Effects
Multiple Sclerosis (MS)
P1
Completed77RCT, Double-blindInterferon beta 1a, (IM) AVONEX®
NCT01215084
A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers
Healthy
P1
Completed36Open-labelBIIB041 (Fampridine-PR)
NCT01424163
Dexpramipexole Japanese PK Study
Amyotrophic Lateral Sclerosis
P1
Completed57Open-labelSingle dose reduced, Single dose standard, Multiple Dose, Multiple Dose
NCT01598363
An Open-Label Study of the Effect of Bardoxolone Methyl on the Single Dose Pharmacokinetics of Digoxin and Rosuvastatin in Healthy Volunteers
Healthy Volunteers
P1
Completed32RCT, Open-labelDigoxin, Rosuvastatin
NCT00651443
Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma
Lymphoma, Non-Hodgkin's
P1
Terminated20Open-labelGaliximab
NCT06264440
A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants
Healthy Volunteer
P1
Completed18Open-labelBIIB122, Rabeprazole
NCT01119781
A Single-Dose, Pharmacokinetic/Pharmacodynamic (PK/PD), & Safety Study of BIIB017 in Participants With Renal Impairment & Healthy Volunteers
Healthy, Renal Insufficiency
P1
Completed35Open-labelBIIB017(peginterferon beta-1a)
NCT00319930
Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL
Chronic Lymphocytic Leukemia
P1
Terminated10Open-labelCNF1010 (17-AAG)
NCT00555724
Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors
Solid Tumors
P1
Completed40Open-labelBIIB022
NCT00970580
A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
P1
Completed18Open-labelBIIB022 With Paclitaxel and Carboplatin
NCT02555085
Single Ascending Doses of BIIB063 in Healthy Volunteers
Healthy
P1
Terminated29RCT, Double-blindBIIB063
NCT02831517
PK and Safety Study of BIIB074 in Healthy Japanese and Caucasian Participants
Healthy, Trigeminal Neuralgia
P1
Completed64RCT, Double-blindBIIB074, Placebo
NCT02071121
Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food Effect
Healthy
P1
Completed39RCT, Double-blindBIIB061, Placebo, 14C-BIIB061
NCT01689116
Multiple-Dose Study of Effect of Bardoxolone Methyl on QT/QTC Interval Volunteers
Healthy Volunteers
P1
Completed179RCT, Double-blindBardoxolone Methyl 20mg, Bardoxolone Methyl 80mg, Bardoxolone Methyl Placebo, Moxifloxacin 400mg, Moxifloxacin Placebo
NCT01069913
Pharmacokinetics Profile Study of BG00012 Standard Formulation and BG00012 Active Pharmaceutical Ingredient
Healthy
P1
Completed14RCT, Open-labelBG00012
NCT06640933
A Study to Find Out How Different Forms of BIIB091 is Processed in The Body With and Without Food in Healthy Participants
Healthy Volunteer
P1
Completed25RCT, Open-labelBIIB091
NCT00529113
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
Pancreatic Neoplasms, Pancreatic Cancer
P1
Terminated33RCT, Open-labelBardoxolone methyl, Bardoxolone methyl, Bardoxolone methyl, Bardoxolone methyl, Bardoxolone methyl, Bardoxolone methyl, Bardoxolone methyl, Gemcitabine, Placebo, Bardoxolone methyl
NCT01453426
Phase 1 Study to Evaluate the PK, Safety, and Tolerability of BG00012 in Chinese, Japanese, and Caucasian Healthy Volunteers
Healthy
P1
Completed71RCT, Open-labelBG00012 Dose 1, BG00012 Dose 2
NCT04106050
Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic Polyneuropathy
Healthy Volunteers, Diabetic Neuropathies
P1
Withdrawn—RCT, Double-blindBIIB095, BIIB074, Placebo, Lidocaine
NCT03716570
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease
Parkinson's Disease
P1
Terminated24RCT, Double-blindBIIB054, Placebo
NCT06064929
A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old
Lupus Nephritis
P1
Completed14Open-labelFelzartamab
NCT01500408
Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers
Multiple Sclerosis
P1
Completed110RCT, Single-blindInterferon beta-1a (current approved manufacturing process invloving FBS), Interferon beta-1a (new process, manufactured without FBS)
NCT00964288
Effect of GSK1014802 on Electrical Hyperalgesia and Threshold Tracking in Healthy Subjects
Pain, Neuropathic, Neuropathic Pain
P1
Terminated16RCT, Double-blindGSK1014802 low dose, Lidocaine, GSK1014802 high dose, Placebo
NCT01405833
Study of the Safety, Tolerability, Pharmacokinetics and Safety of BG00010 (Neublastin) in Subjects With Sciatica.
Sciatica
P1
Completed56RCT, Double-blindBG00010 (Neublastin), Placebo
NCT04571424
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB133 (Dapirolizumab Pegol) in Healthy Japanese and Caucasian Participants
Healthy Volunteers
P1
Completed33RCT, Double-blindBIIB133 (Dapirolizumab pegol), Placebo
NCT00837785
A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS
Relapsing Remitting Multiple Sclerosis
P1
Completed48RCT, Open-labelBG00012, BG00012
NCT05148481
A Study to Evaluate Safety and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants
Healthy Volunteer
P1
Completed31RCT, Double-blindBIIB104, Placebo
NCT01780246
An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1 (NCT01494701)
Spinal Muscular Atrophy
P1
Completed18Open-labelnusinersen
NCT02052791
An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246)
Spinal Muscular Atrophy
P1
Completed47Open-labelnusinersen
NCT01518894
A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia
Schizophrenia
P1
Completed30RCT, Double-blindPF-04958242, PF-04958242, PF-04958242, Placebo
NCT01420458
Study in Healthy Volunteers to Establish the BioEquivalence of Two Formulations of BG00012
Healthy Volunteers
P1
Completed80RCT, Open-labelExperimental
NCT01313364
A Safety Study in Healthy Volunteers of the Single-Use Autoinjector Containing Placebo of BG9418 Interferon Beta-1a With a 25-Gauge × 1-Inch Needle
Healthy
P1
Terminated80Open-label—
NCT02106897
Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 (Litifilimab) in Healthy Volunteers and Participants With Systemic Lupus Erythematosus
Systemic Lupus Erythematosus, Healthy Volunteers
P1
Completed109RCT, Double-blindBIIB059 (litifilimab), Placebo
NCT00955396
Study to Investigate the Effect of GSK1014802 on Ambulatory Blood Pressure
Healthy Volunteer
P1
Completed60RCT, Double-blindGSK1014802, Placebo
NCT00000721
An Escalating Dose Tolerance Trial of BG8962 (rCD4) in Patients Who Are HIV Antibody Positive
HIV Infections
P1
Completed85Open-labelCD4 Antigens
NCT05927649
A TQTc Study for Omaveloxolone
Health Adult Subjects
P1
Completed30RCT, Double-blindOmaveloxolone, Moxifloxacin
NCT02359344
PK & Tolerability of CNV1014802 in Young and Elderly Healthy Volunteers
Trigeminal Neuralgia
P1
Completed32RCT, Double-blindCNV1014802, Placebo
NCT00488566
GSK Drug Single Dose Escalation And Their Effect On Resting Motor Threshold In Healthy Volunteers
Bipolar Disorder
P1
Completed50RCT, Double-blindGSK drug
NCT01416207
A Multiple-Dose, Open-Label, Phase 1, Pharmacokinetic, Pharmacodynamic, and Safety Study of Avonex® in Chinese Healthy Volunteer Subjects
Healthy
P1
Completed24Open-labelAvonex
NCT02171208
A Healthy Volunteer Study to Establish the Bioequivalence of BG00012 Supplied by 2 Different Commercial Manufacturers
Healthy
P1
Completed80RCT, Double-blinddimethyl fumarate - Reference form, dimethyl fumarate - Test form
NCT01646840
Study Of The PF-04958242 Blood Concentrations Of A Capsule Formulation Of PF-04958242 Compared To A Solution Formulation
Healthy
P1
Completed12RCT, Open-labelPF-04958242 capsule, PF-04958242 oral solution
NCT02641041
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants
Central Nervous System (CNS) Demyelinating Disease, Multiple Sclerosis
P1
Completed24RCT, Double-blindBIIB033
NCT01132703
Safety Study of RP-1127 (Glyburide for Injection) in Healthy Volunteers
Traumatic Brain Injury, Stroke
P1
Completed34RCT, Double-blindGlyburide for Injection, Placebo
NCT00908154
Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802.
Bipolar Depression, Bipolar Disorder
P1
Completed51RCT, Double-blindPlacebo, GSK1014802
NCT01503866
A Phase I Study to Investigate the Absorption, Metabolism and Excretion in Healthy Male Subjects
Healthy
P1
Completed6Open-labelbardoxolone methyl
NCT03454126
Evaluating the Safety, Tolerability, and Pharmacokinetics of BIIB095 in Healthy Participants
Healthy Volunteer
P1
Completed80RCT, Double-blindBIIB095, Placebo
NCT02698267
Effect of Itraconazole on the Pharmacokinetics of BIIB074
Neuropathic Pain
P1
Completed16Open-labelBIIB074, Itraconazole
NCT01610310
Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy Volunteers
Healthy, Multiple Sclerosis
P1
Completed55RCT, Open-label—
NCT01365338
A Study To Assess Effects Of PF-04958242 On Bold Functional Magnetic Resonance Imaging During Working Memory Activation And Arterial Spin Labeling At Rest In Healthy Subjects
Healthy Volunteer
P1
Completed112RCT, Double-blindPlacebo, PF-04958242
NCT02521545
Single-Dose Study of a New Formulation of BIIB061
Multiple Sclerosis
P1
Completed8Open-labelBIIB061
NCT00299962
Gene Therapy for Pleural Malignancies
Pleural Mesothelioma, Metastatic Pleural Effusions
P1
Completed17Open-labelAdenoviral-mediated Interferon-beta, SCH 721015
NCT01119677
A Study of Avonex to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy Volunteers
Healthy Volunteers
P1
Completed120RCT, Double-blindAvonex
NCT02029729
RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER
Metastatic or Incurable Non-small Cell Lung Cancer, Relapsed, Refractory Melanoma
P1
Completed11Open-labelomaveloxolone
NCT05229562
A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants
Healthy Volunteer
P1
Completed84Open-labelBIIB122
NCT03284931
A Study to Assess the Pharmacodynamic Effects of SAGE-217 in Healthy Adults Using an Insomnia Model
Healthy
P1
Completed45RCT, Double-blindSAGE-217 high dose, Placebo, SAGE-217 low dose
NCT02228395
Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers
Healthy
P1
Completed12RCT, Double-blindPF-04958242, Placebo
NCT02125578
A Multiple Dose Safety Study of PEG-IFN in Healthy Volunteers
Healthy
P1
Completed69RCT, Double-blindBIIB017 (PEGylated Interferon Beta-1a), Placebo
NCT05216887
A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy Volunteers
Healthy Volunteer
P1
Completed123RCT, Open-labelAducanumab
NCT01549769
Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes
Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
P1
Terminated24Open-labelBardoxolone Methyl
NCT01842126
Phase 1 Subcutaneous Single and Multiple Ascending Dose Study of BG00010 (Neublastin)
Painful Lumbar Radiculopathy, Healthy
P1
Completed54RCT, Double-blindBG00010 IV, BG00010 SC, Placebo IV, Placebo SC
NCT00913250
A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy Volunteers
Multiple Sclerosis
P1
Completed96RCT, Single-blindSerum containing Avonex, Serum Free Avonex
NCT01035515
BIIB014 Cardiovascular Monitoring Study
Healthy
P1
Completed24RCT, Double-blindPlacebo, BIIB014 50mg, BIIB014 100mg
NCT04002492
Effects of a Weight Based Training Program on MS Patients
Multiple Sclerosis
N/A
Unknown25Open-label—
NCT03554343
Sun May Arise on SMA : Newborn Screening of Spinal Muscular Atrophy in Belgium
Spinal Muscular Atrophy
Completed136,339——
NCT05260151
Tau Protein and SV2a Imaging in Patients With Tau Protein-related Diseases
Alzheimer Disease, Progressive Supranuclear Palsy
Unknown155——
NCT01056848
International, Multicenter Study of a Twenty-eight Week, Open-label, Titrated Oral Lixivaptan Administration in Patients With Chronic Hyponatremia: Extension to Studies CK-LX3401, 3405, and 3430
Hyponatremia With Normal Extracellular Fluid Volume, Hyponatremia With Excess Extracellular Fluid Volume
Completed135——
NCT00443443
A Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti-TNF Therapy (SUNSTONE)
Rheumatoid Arthritis
Completed1,026——
NCT02778438
A Validation Study of the Novel Application of Telehealth in Clinical Drug Development in Subjects With Mild Cognitive Deficits
Mild Cognitive Impairment, Alzheimer's Disease
Completed30——
NCT05058950
An Observational Study Using Multimodal Sensors to Measure Cognitive Health in Adults and Distinguish Mild Cognitive Impairment From Normal Aging
Mild Cognitive Impairment, Normal Aging
Terminated22,720——
NCT04288128
Integrated Functional Evaluation of the Cerebellum
Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 7
Completed40——
NCT03347370
A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Completed626—SC Peginterferon beta-1a, SC interferon beta-1a, SC interferon beta-1b
NCT01532154
Fampridine Pregnancy Exposure Registry
Multiple Sclerosis, Pregnancy
Terminated1—Fampridine
NCT03498625
Crohn's Disease Endoscopic REmission Definition in an Objective Way
CD
N/A
Completed240Open-label—
NCT00884481
Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS
Relapsing-Remitting Multiple Sclerosis, Fatigue
Completed195——
NCT02644083
Tecfidera and MRI for Brain Energy in MS
Multiple Sclerosis
Terminated4—Dimethyl fumarate
NCT02323269
Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)
Multiple Sclerosis, Relapsing-Remitting, Relapsing-Remitting Multiple Sclerosis
Terminated24—dimethyl fumarate
NCT03300869
Natural History of Types 2 and 3 SMA in Taiwan
Spinal Muscular Atrophy
Unknown300——
NCT00223457
Factors That Influence Compliance With Disease-Modifying Therapy in Multiple Sclerosis
Multiple Sclerosis
Completed1,040——
NCT05197699
Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multiple Sclerosis (MS) Vaccination Study
Multiple Sclerosis (MS)
Terminated160——
NCT02422407
A Longitudinal, Observational Biomarker Study in Participants With Primary Sjogren's Syndrome
Healthy, Sicca Syndrome
Completed100——
NCT06127095
A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments
Multiple Sclerosis, Relapsing-Remitting
Completed474——
NCT00937677
Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study
Multiple Sclerosis
Completed85—Tysabri
NCT01706107
Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants
Relapsing-Remitting Multiple Sclerosis
Terminated73——
NCT04795206
Natural Disease Progression in Participants With Choroideremia
Choroideremia
Completed1,178——
NCT01943526
Ireland Natalizumab (TYSABRI) Observational Program
Relapsing-Remitting Multiple Sclerosis
Completed191—natalizumab
NCT02137109
Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri
Multiple Sclerosis
Completed400—natalizumab
NCT03593499
Expanded Access to Omaveloxolone for Melanoma for Patients Previously Enrolled in 408-C-1401
Melanoma
NO_LONGER_AVAILABLE——omaveloxolone
NCT01405872
Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™.
Multiple Sclerosis
Completed270——
NCT01070836
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
Relapsing Multiple Sclerosis
Completed35,895—natalizumab
NCT03359551
Natural History of the Progression of Choroideremia Study
Choroideremia
Completed319——
NCT02839460
A Prospective Study Of Biomarkers Of Skeletal Muscle Atrophy
Sarcopenia
Completed30——
NCT04145284
Quantitative Magnetic Resonance Imaging (MRI) Sub-Study of MS PATHS
Multiple Sclerosis
Completed6——
NCT01211678
Biomarkers of Anti-TNF-α Therapy Efficacy in Rheumatoid Arthritis to Define Unresponsive Patients
Arthritis, Rheumatoid
Completed301——
NCT01156298
Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance
Multiple Sclerosis
Terminated383——
NCT00493298
Tysabri Observational Program
Relapsing-Remitting Multiple Sclerosis
Completed6,620—Tysabri
NCT05354414
Virtual Reality for the Mitigation of Anxiety During Intrathecal Administration in Participants With Spinal Muscular Atrophy
Spinal Muscular Atrophy (SMA)
N/A
Completed63RCT, Open-label—
NCT03662919
One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study
Arthritis, Rheumatoid, Spondylitis, Ankylosing
Completed2,274—Infliximab, Adalimumab
NCT00464074
Evaluation of Natalizumab for thE Relief of MS Associated FatiGue
Multiple Sclerosis
Completed89——
NCT01211639
Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy
Progressive Multifocal Leukoencephalopathy
Terminated24——
NCT00483847
TYGRIS - ROW: TYSABRI Global Observational Program in Safety - Rest of World
Multiple Sclerosis
Completed4,296——
NCT02440126
Longitudinal Analysis And Sample Collection To Evaluate PML Risk Host Markers for PML Risk Host Markers for PML Risk
Multiple Sclerosis
Completed196——
NCT04103333
Angelman Syndrome (AS) Biomarker Study
Angelman Syndrome, Chromosome 15q Duplication (dup15q) Syndrome
Early P1
Completed20Open-label—
NCT05561621
Prediction of Non-motor Symptoms in Fully Ambulatory MS Patients Using Vocal Biomarkers
Multiple Sclerosis
Completed70——
NCT00472992
Pregnancy Exposure Registry for Tysabri®
Crohn's Disease, Prenatal Exposure
Completed376——
NCT04089514
A Real-world Study of Imraldi® Use
Arthritis, Rheumatoid (RA), Axial Spondyloarthritis (axSpA)
Completed1,000—Adalimumab
NCT02099370
Adherence to Treatment With Tecfidera™ in Multiple Sclerosis Patients
Multiple Sclerosis
Completed34——
NCT00477113
TYSABRI Global Observational Program in Safety
Multiple Sclerosis
Completed2,207——
NCT00422617
Evaluate the Efficacy and Safety of One Course of Amevive in Taiwan Patients
Chronic Plaque Psoriasis
N/A
Completed40Open-labelAlefacept (Amevive)
NCT00599274
Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis
Multiple Sclerosis
Completed136—Interferon beta-1a, Interferon beta-1a
NCT01945359
Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design
Relapsing Remitting Multiple Sclerosis
Completed30——
NCT01816100
The Effect of Exercise on Strength and Mobility and Corresponding CNS Plasticity in Multiple Sclerosis Patients
Multiple Sclerosis
N/A
Completed6Open-label—
NCT01489748
Canadian Avonex PEN Productivity Study
Multiple Sclerosis
Completed111——
NCT02996084
MS PATHS Normative Sub-Study
Healthy Volunteer
Completed246——
NCT02386566
Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab
Multiple Sclerosis
Completed48—natalizumab
NCT04750785
A Study to Assess Choroideremia (CHM) Health Outcomes
Choroideremia
Completed46——
NCT05109637
A Study to Assess the Clinical Validity of Konectom™ in Adults Living With Neuromuscular Disorders
Spinal Muscular Atrophy
N/A
Completed93Open-label—
NCT02865109
Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)
Infantile-onset Spinal Muscular Atrophy
NO_LONGER_AVAILABLE——Nusinersen
NCT06602921
The Effects of Nitrate, Caffeine, and Cold Exposure on Cardiovascular Function.
Nitrate, Caffeine
N/A
Completed24RCT, Double-blind—
NCT00675883
COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS
Multiple Sclerosis, Relapsing-Remitting
Completed1,000——
NCT01185717
JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)
Multiple Sclerosis
Completed7,726——
NCT00618267
ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.
Multiple Sclerosis
Completed100——
NCT02686268
Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS
C9ORF72 Amyotrophic Lateral Sclerosis (ALS)
Completed128——
NCT01626248
Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control
Multiple Sclerosis
Completed164——
NCT04972487
Expanded Access Program for Tofersen in Participants With Superoxide Dismutase 1-Amyotropic Lateral Sclerosis
Superoxide Dismutase 1-Amyotropic Lateral Sclerosis
APPROVED_FOR_MARKETING——Tofersen
NCT05446285
Multiple Sclerosis Outcome Determination Evaluating Real Differences After TimE
Relapsing Remitting Multiple Sclerosis
Unknown245——
NCT00463710
Effect of Interferon Beta-1a (Avonex®) on Changes of Non-conventional MRI Measures in Patients With MS
Multiple Sclerosis
Completed150—Avonex® monotherapy (6.0 MIU administered i.m. each week)
NCT00288990
A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarker Response in Patients With Multiple Sclerosis
Multiple Sclerosis
Completed300——
NCT03662750
TSPO PET as a Measure of Post-stroke Brain Inflammation: a Natural History Cohort
Stroke, Ischemic, Inflammatory Response
N/A
Completed3Open-label—
NCT04221191
Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEP
Multiple Sclerosis, Relapsing-Remitting
Completed353—Dimethyl Fumarate
NCT02308657
Multicenter Observational Study of Myotonic Dystrophy Type 1
Myotonic Dystrophy Type 1
Completed120——
NCT05097131
An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US
Alzheimers Disease
Terminated29——
NCT05058729
MS PATHS COVID-19 Questionnaire Data Linkage Sub-Study
Multiple Sclerosis (MS)
Completed1,507——
NCT02664324
MSPT Device Usability Study
Multiple Sclerosis
Completed60——
NCT04268147
Instrumented Data Exchange for Ataxia Study
Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2
Completed128——
NCT04419233
Non-Interventional, Postmarketing Surveillance Study of Nusinersen Sodium Injection
Muscular Atrophy, Spinal
Completed50—Nusinersen Sodium Injection
NCT07887828
A Study to Learn More About Friedrich's Ataxia in People Living in the Gulf Cooperation Council (GCC) Region of the World
Friedreich's Ataxia
Not Yet Recruiting40——
NCT04832399
Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants
Relapsing Remitting Multiple Sclerosis
Completed60—Natalizumab
NCT02125695
Pilot Tape Harvesting Study
Atopic Dermatitis, Healthy
Completed37——
NCT03218111
Glymphatic Kinetics In Healthy Adult Volunteers
Healthy
N/A
Completed19Open-label—
NCT01071512
Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis
Multiple Sclerosis
N/A
Completed20Open-labelTysabri
NCT01330498
Longitudinal Pharmacokinetic, Pharmacodynamic, Immunological, and Biochemical
Multiple Sclerosis
Completed229——
NCT05209815
Safety of Exposure to Natalizumab During Pregnancy
Multiple Sclerosis
Completed68——
NCT02531009
Systemic Sclerosis Clinical and Biomarker Study
Healthy, Systemic Sclerosis
Withdrawn———
NCT00707512
CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring
Crohn's Disease
Terminated87—natalizumab
NCT00424788
A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)
Relapsing Forms of Multiple Sclerosis
Early P1
Completed12Open-labelnatalizumab treatment
NCT01070719
Pharmacokinetic, Immunological and Biochemical Sample Collection and Analysis of a Tysabri Patient Cohort
Multiple Sclerosis, Relapse
Completed270——
NCT02776072
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
Multiple Sclerosis
Completed2,978——
NCT02519413
Tecfidera Lymphocyte Chart Review
Multiple Sclerosis
Completed483—dimethyl fumarate
NCT02749396
EPID Multiple Sclerosis Pregnancy Study
Multiple Sclerosis
Completed2,089—Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG, Extavia (interferon beta-1b), Novartis Pharma AG, Rebif (interferon beta-1a), Merck Serono Europe Ltd, Plegridy (peginterferon beta-1a), Biogen Idec Ltd, Avonex (interferon beta-1a), Biogen Idec Ltd, MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046)
NCT04599023
Assessing the Feasibility of the MSPT Device in Routine Clinical Practice in the Swiss Healthcare System
Multiple Sclerosis, Clinically Isolated Syndrome
Terminated182——
NCT04580381
Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort
Multiple Sclerosis, Relapsing-Remitting
Completed500—Natalizumab Injection [Tysabri]
NCT03327454
Benepali® PEN Patient Satisfaction Survey
Rheumatoid Arthritis, Spondyloarthropathies
Completed500—Benepali
NCT04756687
Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by Tecfidera
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Completed1,507—Dimethyl fumarate
NCT04746976
Study of Diroximel Fumarate in the Real-World Setting
Relapsing Forms of MS
Terminated75—Diroximel Fumarate
NCT01366040
Avonex PEN Satisfaction and Patients Experience Clinical Trial
Multiple Sclerosis
Completed89——
NCT04756700
Validation of DigiCog and Konectom Tools to Support Digitalized Clinical Assessment in Multiple Sclerosis
Multiple Sclerosis
N/A
Completed158RCT, Open-label—
NCT03487900
Is the Endoscopic Remission Evaluation, Using the CREDO 1 Index / Score in CD Patients in Clinical Remission at Baseline, Predictive of Sustained Clinical Remission Using a 2-year Follow up
CD
N/A
Unknown320Open-label—
NCT02076841
Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen
Relapsing-Remitting Multiple Sclerosis, Clinical Isolated Syndrome (CIS)
Completed40——
NCT05701423
A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants
Multiple Sclerosis
Terminated34—Natalizumab
NCT06089018
Observational Study of Digital Biomarkers of Myotonia and Gait in Adults and Children With Myotonic Dystrophy
Myotonic Dystrophy 1
Unknown125——
NCT01592474
Evaluation of Brain Atrophy in CIS Patients on Avonex
Multiple Sclerosis
Completed180——
NCT01485003
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants
Relapsing-Remitting Multiple Sclerosis
Completed231—natalizumab
NCT03926637
Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis
Multiple Sclerosis
Terminated3,073——
NCT01480063
An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice
Multiple Sclerosis
Completed4,734—Fampridine
NCT02969304
Study of Utilization Patterns of Dimethyl Fumarate in Germany
Multiple Sclerosis
Completed930—dimethyl fumarate
NCT00525343
Avonex 15 Year Long Term Follow-up Study
Multiple Sclerosis
Completed122——